AIM ImmunoTech Inc. (AIM) company profile

AIM ImmunoTech Inc. is an immuno-pharma company focused on research and development of therapeutics to treat multiple types of cancer, viral diseases, and immune-deficiency disorders with inadequate or unmet treatments. Its primary products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA molecule being evaluated across various solid tumor types, including late-stage pancreatic cancer, as well as viral illnesses and immune disorders. The company aims to develop treatments for healthcare providers and patients facing severe diseases, including post-COVID conditions and chronic fatigue syndrome.

The company operates out of Ocala, Florida, where its principal executive offices are located. Its clinical trial activities and development collaborations take place internationally, including studies conducted in the Netherlands. Ampligen is approved for commercial sale in the Argentine Republic for severe chronic fatigue syndrome, though it has not received FDA approval or commercial marketing authorization in the United States.

Summary of the business section of AIM ImmunoTech's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.